bluebird bio Inc expected to post a loss of $3.69 a share - Earnings Preview

bluebird bio

05/05/2025 14:07

bluebird bio Inc BLUE.OQ BLUE.O is expected to show a rise in quarterly revenue when it reports  results on May 7 (estimated) for the period ending March 31 2025

The Somerville Massachusetts-based  company is expected to report a 104.1% increase in revenue to $37.9 million from $18.57 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.

​LSEG's mean analyst estimate for bluebird bio Inc is for a loss of $3.69 per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 0.6% in the last three months. ​

Wall Street's median 12-month price target for bluebird bio Inc is $8.00​, above​ its last closing price of $3.95. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-5.13
-5.98
-2.95
Beat
50.6
Sep. 30 2024
-6.65
-7.29
-6.20
Beat
14.9
Jun. 30 2024
-9.96
-8.33
-8.40
Missed
-0.8​
Mar. 31 2024
-8.83
-8.81
-7.20
Beat
18.3
​​Dec. 31 2023
-13.01
-13.24
-15.60
Missed
-17.8
Sep. 30 2023
-13.45
-13.50
-13.20
Beat
2.2​
Jun. 30 2023
-14.37
-14.31
-13.40
Beat
6.4
Mar. 31 2023
-5.37
-7.40
4.20
Beat
156.8

This summary was machine generated May 5 at 13:07 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)